MK-677

Dylan Gemelli notes that when he began researching peptides and SARMs in 2011, he found studies dating back to the 1990s for MK-2866 (Ostarine) and MK-677 (Ibutamoren). While MK-2866 and MK-677 are technically SARMs/secretagogues rather than classical peptides, they were discussed in the same context as peptides in the early underground research community. No specific study details or dosages are referenced from these older studies.

The protocol includes CJC-1295 (administered for seven days) to provide a stable pulse of growth hormone-releasing hormone and elevate IGF-1 in the liver. This is paired with MK-677, an oral ghrelin agonist that profoundly boosts GH and IGF-1 while improving sleep quality and cellular regeneration. The speaker explicitly warns against exogenous HGH due to side effects.

The video provides a comparative framework across five GH-influencing compounds: Tesamorelin, CJC-1295, Ipamorelin, MK-677, and Sermorelin. Key differentiators include mechanism of action (GHRH analog vs. ghrelin receptor activation), strength of pulsatile GH response, IGF-1 elevation, cortisol risk, appetite stimulation, and insulin sensitivity impact. Sermorelin is mentioned by name as a comparator but no specific claims about it are elaborated upon in the transcript.

MK-677 (a non-peptide ghrelin mimetic often grouped with GH-axis peptides) has been shown to increase appetite as a side effect. Additionally, it can blunt insulin sensitivity in some individuals, representing a meaningful metabolic safety concern. No dosages or study citations are provided.

MK-677 carries a safety concern regarding potential impairment of insulin sensitivity in some people. This is presented as a metabolic risk that distinguishes it from other GH-stimulating peptides. The effect appears to be individual-dependent ('in some people'), and no dosages or specific study data are cited.

MK-677, a ghrelin mimetic that stimulates GH release, has been shown to increase appetite as a notable side effect. This is flagged as a practical consideration for patients or users. No dosages or study citations are provided.

Ben Greenfield warns that ipamorelin, sermorelin, and MK-677 all target the same growth hormone receptors and stacking them creates exponentially compounded side effects without proportional benefit. He uses this as an example of how biohackers create dangerous redundancy by combining compounds with overlapping mechanisms of action. No specific dosages are mentioned, but the warning applies to any combination of these GH-axis compounds.

MK-677 is a non-selective GHS-R1A agonist that causes elevated cortisol (muscle wasting, metabolic problems) and elevated prolactin (gynecomastia, sexual dysfunction, lactation). Dr. Bachmeyer positions Ipamorelin as the superior choice due to its selectivity, producing GH release without collateral hormonal disruption.